NextCure, Inc. (NASDAQ:NXTC) Receives Consensus Rating of “Hold” from Brokerages

NextCure, Inc. (NASDAQ:NXTC) has been assigned an average recommendation of “Hold” from the five ratings firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $23.00.

A number of equities analysts recently commented on NXTC shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of NextCure in a research note on Monday, April 27th. Zacks Research downgraded NextCure from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 6th.

Hedge Funds Weigh In On NextCure

A number of large investors have recently bought and sold shares of NXTC. Cable Car Capital LP lifted its holdings in NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after acquiring an additional 88,040 shares during the last quarter. Geode Capital Management LLC lifted its holdings in NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after acquiring an additional 3,636 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after acquiring an additional 5,300 shares during the last quarter. Exome Asset Management LLC bought a new position in NextCure in the fourth quarter worth about $2,341,000. Finally, AWM Investment Company Inc. bought a new position in NextCure in the fourth quarter worth about $1,665,000. Institutional investors own 42.65% of the company’s stock.

NextCure Stock Performance

NASDAQ:NXTC opened at $2.95 on Tuesday. The company has a market capitalization of $10.65 million, a price-to-earnings ratio of -0.17 and a beta of 1.30. NextCure has a one year low of $2.83 and a one year high of $15.74. The stock has a 50-day simple moving average of $9.35 and a 200 day simple moving average of $11.26.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, topping analysts’ consensus estimates of ($2.10) by $0.23. On average, equities research analysts forecast that NextCure will post -7.91 EPS for the current fiscal year.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.